EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieOpen access

A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment

Mark J Butler iD, Thevaa Chandereng iD, Heejoon Ahn iD, Stefani Slotnick iD, Danielle Miller iD, Alexandra Perrin iD, Jordyn Rodillas iD, Ciaran P Friel iD, Ashley M Goodwin iD, Ying Kuen Cheung iD, Karina W Davidson iD

JMIR Formative Research · 2025

DOI: 10.2196/58192 ↗

At a glance

Randomisierte kontrollierte Studie in JMIR Formative Research, 2025. Written by Mark J Butler and 10 co-authors. Institution: Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042-1069, United States, 1 6467667181. Major MEDLINE topics: Melatonin, Dietary Supplements, Sleep Initiation and Maintenance Disorders, Precision Medicine. Cited 1 times so far (Crossref); 80 references. The full text is freely available in PubMed Central. Funded by: NIH HHS.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogenous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient.

Objective

This study aimed to identify the feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep.

Methods

This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0 mg and 0.5 mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial comprised a 2-week baseline period and a 12-week intervention period. The primary outcomes were usability of the personalized trial system (measured using the System Usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker [Google]) and sleep quality (measured using the consensus sleep diary).

Results

Participants rated the usability of the personalized trial as acceptable (average SUS score 76.3, SD 17.1), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0 mg and 0.5 mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0 mg ( P =.70) and 0.5 mg ( P =.90) melatonin intervention periods and the baseline period. In addition, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality.

Conclusions

Participant ratings of the usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Furthermore, the treatment effects’ lack of heterogeneity among participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.

Subjects

MeSH terms (MEDLINE)

MelatoninDietary SupplementsSleep Initiation and Maintenance DisordersPrecision MedicineHumansCross-Over StudiesMaleFemaleFeasibility StudiesMiddle AgedAdultTreatment OutcomeAgedSleepSleep QualityPatient Satisfaction

Author keywords

FitbitN-of-1effectivenessfeasibilityheterogeneityinterventionmelatoninpersonalizedpersonalized trialplacebopoor sleeprandomized crossover trialsleep durationsleep healthsleep quality

Substances

Melatonin

Authors and institutions

  • Northwell, 2000 Marcus Ave, Suite 300, New Hyde Park, NY, 11042-1069, United States, 1 6467667181.
  • Institute of Health System Science, Feinstein Institutes For Medical Research, Manhasset, NY, United States.
  • Mailman School of Public Health, Columbia University, New York, NY, United States.

ORCID profiles: Mark J Butler, Thevaa Chandereng, Heejoon Ahn, Stefani Slotnick, Danielle Miller, Alexandra Perrin, Jordyn Rodillas, Ciaran P Friel, Ashley M Goodwin, Ying Kuen Cheung, Karina W Davidson

Funding

  • NIH HHS

Cite

APA

Butler, M. J., Chandereng, T., Ahn, H., Slotnick, S., Miller, D., Perrin, A., Rodillas, J., Friel, C. P., Goodwin, A. M., Cheung, Y. K., & Davidson, K. W. (2025). A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment. JMIR Formative Research. https://doi.org/10.2196/58192

Vancouver

Butler MJ, Chandereng T, Ahn H, Slotnick S, Miller D, Perrin A, et al. A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment. JMIR Formative Research. 2025. doi:10.2196/58192

BibTeX
@article{Butler2025,
  author = {Butler, Mark J and Chandereng, Thevaa and Ahn, Heejoon and Slotnick, Stefani and Miller, Danielle and Perrin, Alexandra and Rodillas, Jordyn and Friel, Ciaran P and Goodwin, Ashley M and Cheung, Ying Kuen and Davidson, Karina W},
  title = {A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: Feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment},
  journal = {JMIR Formative Research},
  year = {2025},
  doi = {10.2196/58192}
}
Start for free →